查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2137155

Filgrastim及其生物相似藥市場：全球市場預測，2026-2032年

Filgrastim & Biosimilars Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，Filgrastim及其生物相似藥市場將成長至 40.2 億美元，複合年成長率為 15.67%。

主要市場統計數據
基準年 2025 14.5億美元
預計年份：2026年 16.4億美元
預測年份 2032 40.2億美元
複合年成長率 (%) 15.67%

Filgrastim及其生物相似藥：市場趨勢概述

Filgrastim是一種重組顆粒細胞增生因子，用於縮短化療及其他涉及骨髓抑制的臨床情況下中性粒細胞減少嗜中性白血球低下症的持續時間並降低感染風險。生物相似藥透過來源多元化和支持更系統化的生物製藥採購方法，拓寬了治療範圍。市場發展受臨床可靠性、監管等效性標準、醫院規程、報銷方案設計、生產可靠性和治療可及性等因素的影響。

競爭與採購如何改變Filgrastim的使用

當前情勢正從依賴單一生物製藥品牌轉向從多家供應商採購以及採用實證替代政策。醫院和公共醫療系統更重視治療總成本、供應連續性、互換性法規、冷鏈運作和藥物安全監測。這些變化有利於那些能夠證明產品品質穩定、分銷可靠，並為臨床醫生和藥劑師提供實際支持，同時又能維持患者對生物相似藥信心的供應商。

人工智慧正在改善需求、安全和供應方面的決策。

人工智慧 (AI) 可透過分析治療方案、庫存波動、使用模式和不利事件報告來最佳化Filgrastim計劃。預測工具可以幫助醫療服務提供者識別需求高峰、減少不必要的缺貨，並優先安排分散式醫療網路中的補貨。在臨床實踐中，AI 驅動的決策支援可以輔助風險分層和方案監測，但其輸出結果需要檢驗、手動監督、健全的資料管治，並符合適用的醫療資料和醫療設備要求。

六個醫療保健環境的區域洞察

北美地區擁有完善的腫瘤治療基礎設施、支付方嚴格的審查機制以及詳盡的生物製藥替代流程。歐洲則著重於集中評估、國家層級的報銷決策以及在注重成本效益的醫療保健體系中採用生物相似藥。亞太地區癌症治療能力不斷提升，監管和報銷環境高度多樣化。拉丁美洲受制於對公共採購、進口的依賴以及主要都會區與其他地區之間醫療資源取得的差異。中東地區正加大對專科醫療和地方醫療體系的投入，但採購協調和監管成熟度因市場而異。非洲在醫療資源取得、可負擔性、診斷和供應鏈方面持續面臨許多限制，因此可靠的分銷和完善的公共衛生採購機制尤其重要。

區域洞察：東協、金磚國家、歐盟、七國集團、海灣合作理事會、北約

在東協，監管路徑、醫療預算和生產能力的多樣性為建構適應當地情況的藥品取得模式提供了機會。在金磚國家，儘管病患需求量龐大，但各國在國內生產、公共採購和監管審查的做法卻不盡相同。歐盟擁有統一的科學和監管原則，但各國的醫療保險報銷和醫院採購決策仍有差異。七國集團（G7）的醫療體系通常將先進的腫瘤治療服務與嚴格的實證醫學、安全性和預算要求相結合。海灣合作理事會（GCC）國家正在加強其專科醫療體系，並經常採用協調一致的採購方式。同時，北約成員國的醫療體係既有成熟的，也有新興的，它們的緊急準備重點可能會促使它們更加關注具有韌性的藥品供應鏈。

國家層面關於准入、監管和供應的優先事項

澳洲和加拿大在協調報銷和分發方面面臨實際挑戰，以服務於地域分散的人口。巴西和墨西哥需要平衡公共部門採購、地方層級的准入以及區域差異。中國和印度面臨巨大的治療需求，同時法律規範也在不斷發展，並且對國內生物製藥能力的興趣日益濃厚。法國、德國、義大利、西班牙和英國則不斷評估透過國家或區域採購、處方和替代政策來採用生物相似藥的可能性。日本強調嚴格的品質標準和系統化的報銷管理。韓國正在推動先進生技藥品生產能力和醫療保健系統的發展。俄羅斯的情況受國內供應優先事項和不斷變化的准入條件的影響。美國則持續關注替代性、保險公司政策、醫療服務提供者的採納以及供應韌性。

Filgrastim取得和供應方面領導者的實際優先事項

產業領導者應建立穩健的多源供應策略，並以經認證的生產能力、冗餘的物流和透明的供不應求監測流程為支援。透過清晰的療效比較證據、對臨床醫生和藥劑師的培訓以及以患者為中心的溝通（解釋生物相似藥的品質和治療的連續性），可以加強臨床應用。各機構應根據當地法規調整合約和報銷方式，衡量藥物轉換和治療連續性的結果，並維護健全的藥物安全監測系統。投資於可互通的數據系統和精心管理的AI將有助於改善需求預測，而與醫療保健系統建立夥伴關係則有助於在不影響品質的前提下擴大藥物可及性。

高階主管評估調查方法

本評估基於所提供的市場範圍（Filgrastim及其生物相似藥），整合了來自監管、臨床、採購、生產、准入和技術促進因素等方面的研究結果。評估內容涵蓋了生物製藥的既定特徵、生物相似藥的研發、腫瘤支持治療、醫療採購以及不同地區醫療體系的差異。區域、群體和國家層級的觀察結果以定性背景資訊而非數值估計值的形式呈現。本評估不包含市場規模估算、市佔率計算、預測以及公司層級的具體聲明。

結論：可及性和可靠性是決定競爭力的關鍵因素。

Filgrastim及其生物相似藥處於癌症治療需求、生物製藥競爭、醫療負擔和供應鏈韌性的交匯點。成功與否取決於可靠的證據、穩定的生產、有效的替代療法支援、值得信賴的分銷以及與當地醫保報銷機制的契合度，而非產品本身的供應情況。那些能夠兼顧營運韌性、負責任的數位化創新以及清晰的相關人員參與的領導企業，將更有能力改善醫療服務的連續性，並在多元化的醫療市場中擴大藥物的可及性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：Filgrastim及生物相似藥市場：依產品類型分類

  • 生物相似藥Filgrastim
    • Accofil
    • 尼貝斯汀
    • 扎爾基奧
  • 原產品： Filgrastim

第8章：Filgrastim及其生物相似藥市場：以劑型分類

  • 預填充式注射器
  • 管瓶

第9章：Filgrastim及生物相似藥市場：依強度分類

  • 300微克
  • 480微克

第10章：Filgrastim與生物相似藥市場：依應用領域分類

  • 化療引起的嗜中性白血球低下症
    • 骨髓惡性腫瘤的治療
    • 固體癌的治療
  • 嚴重慢性嗜嗜中性白血球低下症
  • 幹細胞動員

第11章：Filgrastim與生物相似藥市場：依最終用戶分類

  • 居家照護
  • 醫院
  • 專科診所

第12章：Filgrastim及生物相似藥市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：Filgrastim及生物相似藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：Filgrastim及生物相似藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：Filgrastim及生物相似藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Amgen Inc.
  • Apotex Inc.
  • Biocon Biologics Ltd.
  • Celltrion Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Kyowa Kirin Co. Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第18章 主要專家

Product Code: MRR-961F26FD7FC7

The Filgrastim & Biosimilars Market is projected to grow by USD 4.02 billion at a CAGR of 15.67% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.45 billion
Estimated Year [2026] USD 1.64 billion
Forecast Year [2032] USD 4.02 billion
CAGR (%) 15.67%

Filgrastim and Biosimilars: Executive Market Context

Filgrastim is a recombinant granulocyte colony-stimulating factor used to reduce the duration of neutropenia and the risk of infection associated with myelosuppressive chemotherapy and other clinical settings. Biosimilars have expanded the therapeutic field by introducing additional sources of supply and supporting more structured approaches to biologic procurement. Market development is shaped by clinical confidence, regulatory comparability standards, hospital protocols, reimbursement design, manufacturing reliability, and treatment access.

How Competition and Procurement Are Reshaping Filgrastim Use

The landscape is shifting from reliance on individual biologic brands toward multi-source purchasing and evidence-based substitution policies. Hospitals and public health systems are placing greater emphasis on total treatment cost, supply continuity, interchangeability rules, cold-chain execution, and pharmacovigilance. These changes favor suppliers able to demonstrate consistent quality, dependable distribution, and practical support for clinicians and pharmacists while preserving patient confidence in biosimilar use.

Artificial Intelligence Is Improving Demand, Safety, and Supply Decisions

Artificial intelligence can strengthen filgrastim planning by analyzing treatment schedules, inventory movements, utilization patterns, and adverse-event reports. Predictive tools may help providers identify likely demand peaks, reduce avoidable stockouts, and prioritize replenishment across distributed care networks. In clinical operations, AI-assisted decision support can support risk stratification and protocol monitoring, but its outputs require validation, human oversight, strong data governance, and compliance with applicable health-data and medical-device requirements.

Regional Insights Across Six Healthcare Landscapes

North America is characterized by sophisticated oncology infrastructure, payer scrutiny, and detailed biologic substitution processes. Europe emphasizes centralized assessment, national reimbursement decisions, and biosimilar adoption within cost-conscious health systems. Asia-Pacific combines expanding oncology capacity with highly varied regulatory and reimbursement environments. Latin America is influenced by public procurement, import dependence, and uneven access between major urban centers and broader populations. The Middle East is investing in specialized care and local health-system capacity, while procurement coordination and regulatory maturity vary across markets. Africa continues to face access, affordability, diagnostic, and supply-chain constraints, making reliable distribution and appropriately designed public-health procurement especially important.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN presents a diverse set of regulatory pathways, healthcare budgets, and manufacturing capabilities, creating opportunities for regionally adaptable access models. BRICS economies combine substantial patient needs with differing approaches to domestic production, public procurement, and regulatory review. The European Union benefits from aligned scientific and regulatory principles, although national reimbursement and hospital purchasing decisions remain distinct. G7 systems generally combine advanced oncology services with stringent evidence, safety, and budget requirements. GCC countries are strengthening specialized healthcare capacity and often use coordinated procurement approaches, while NATO members span mature and emerging health systems whose preparedness priorities can increase attention to resilient pharmaceutical supply chains.

Country-Level Priorities for Access, Regulation, and Supply

Australia and Canada face the practical challenge of serving geographically dispersed populations through coordinated reimbursement and distribution. Brazil and Mexico must balance public-sector procurement, local access, and regional disparities. China and India combine large treatment needs with evolving regulatory frameworks and growing interest in domestic biopharmaceutical capability. France, Germany, Italy, Spain, and the United Kingdom continue to evaluate biosimilar uptake through national or regional purchasing, prescribing, and substitution policies. Japan emphasizes rigorous quality expectations and structured reimbursement management. South Korea is developing advanced biologic manufacturing and healthcare capabilities. Russia's environment is shaped by domestic supply priorities and changing access conditions. The United States remains focused on interchangeability, payer policy, provider adoption, and supply resilience.

Practical Priorities for Leaders in Filgrastim Access and Delivery

Industry leaders should build a resilient, multi-source supply strategy supported by qualified manufacturing capacity, redundant logistics, and transparent shortage-monitoring processes. Clinical adoption can be strengthened through clear comparability evidence, clinician and pharmacist education, and patient-centered communication that explains biosimilar quality and treatment continuity. Organizations should tailor contracting and reimbursement approaches to local rules, measure switching and persistence outcomes, and maintain robust pharmacovigilance. Investment in interoperable data systems and carefully governed AI can improve demand planning, while partnerships with health systems can help extend access without compromising quality.

Research Methodology for the Executive Assessment

This assessment uses the supplied market scope-filgrastim and its biosimilars-and organizes findings around regulatory, clinical, procurement, manufacturing, access, and technology drivers. Insights are synthesized from established characteristics of biologic medicines, biosimilar development, oncology-supportive care, healthcare purchasing, and regional health-system variation. Regional, group, and country observations are presented as qualitative context rather than numerical estimates. No market sizing, market-share calculations, forecasts, or company-specific claims are included.

Conclusion: Access and Reliability Will Define Competitive Strength

Filgrastim and biosimilars are positioned at the intersection of oncology demand, biologic competition, healthcare affordability, and supply-chain resilience. Success will depend less on product availability alone than on credible evidence, consistent manufacturing, effective substitution support, dependable distribution, and alignment with local reimbursement systems. Leaders that combine operational resilience with responsible digital innovation and clear stakeholder engagement will be better placed to improve continuity of care and broaden access across diverse health markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Filgrastim & Biosimilars Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biosimilar Filgrastim
    • 7.2.1. Accofil
    • 7.2.2. Nivestim
    • 7.2.3. Zarxio
  • 7.3. Originator Filgrastim

8. Filgrastim & Biosimilars Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Prefilled Syringe
  • 8.3. Vial

9. Filgrastim & Biosimilars Market, by Strength

  • 9.1. Introduction
  • 9.2. 300 Microgram
  • 9.3. 480 Microgram

10. Filgrastim & Biosimilars Market, by Application

  • 10.1. Introduction
  • 10.2. Chemotherapy Induced Neutropenia
    • 10.2.1. Hematologic Malignancy Treatment
    • 10.2.2. Solid Tumor Treatment
  • 10.3. Severe Chronic Neutropenia
  • 10.4. Stem Cell Mobilization

11. Filgrastim & Biosimilars Market, by End User

  • 11.1. Introduction
  • 11.2. Homecare
  • 11.3. Hospital
  • 11.4. Specialty Clinic

12. Filgrastim & Biosimilars Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Filgrastim & Biosimilars Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Filgrastim & Biosimilars Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Filgrastim & Biosimilars Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Amgen Inc.
  • 17.2. Apotex Inc.
  • 17.3. Biocon Biologics Ltd.
  • 17.4. Celltrion Inc.
  • 17.5. Fresenius Kabi AG
  • 17.6. Intas Pharmaceuticals Ltd.
  • 17.7. Kyowa Kirin Co. Ltd.
  • 17.8. Pfizer Inc.
  • 17.9. Sandoz International GmbH
  • 17.10. Teva Pharmaceutical Industries Ltd.
  • 17.11. Viatris Inc.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Filgrastim & Biosimilars Market, Years Considered for the Study
  • FIGURE 2. Global Filgrastim & Biosimilars Market, Research Design
  • FIGURE 3. Global Filgrastim & Biosimilars Market, Research Framework
  • FIGURE 4. Global Filgrastim & Biosimilars Market, Data Triangulation
  • FIGURE 5. Global Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Filgrastim & Biosimilars Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Filgrastim & Biosimilars Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Filgrastim & Biosimilars Market Size, by Dosage Form, 2025 vs 2032 (%)
  • FIGURE 9. Global Filgrastim & Biosimilars Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Filgrastim & Biosimilars Market Size, by Strength, 2025 vs 2032 (%)
  • FIGURE 11. Global Filgrastim & Biosimilars Market Size, by Strength, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Filgrastim & Biosimilars Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global Filgrastim & Biosimilars Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Filgrastim & Biosimilars Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Filgrastim & Biosimilars Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Filgrastim & Biosimilars Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global Filgrastim & Biosimilars Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Filgrastim & Biosimilars Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Filgrastim & Biosimilars Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Filgrastim & Biosimilars Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Filgrastim & Biosimilars Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Filgrastim & Biosimilars Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Filgrastim & Biosimilars Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Filgrastim & Biosimilars Market Segmentation & Coverage
  • TABLE 2. Global Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Biosimilar Filgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Biosimilar Filgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Biosimilar Filgrastim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Accofil Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Accofil Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Accofil Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Nivestim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Nivestim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Nivestim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Zarxio Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Zarxio Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Zarxio Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Originator Filgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Originator Filgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Originator Filgrastim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 20. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 27. Global 300 Microgram Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global 300 Microgram Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global 300 Microgram Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global 480 Microgram Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global 480 Microgram Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global 480 Microgram Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 34. Global Chemotherapy Induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Chemotherapy Induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Chemotherapy Induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Hematologic Malignancy Treatment Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Hematologic Malignancy Treatment Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Hematologic Malignancy Treatment Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Solid Tumor Treatment Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Solid Tumor Treatment Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Solid Tumor Treatment Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Severe Chronic Neutropenia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Severe Chronic Neutropenia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Severe Chronic Neutropenia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Stem Cell Mobilization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Stem Cell Mobilization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Stem Cell Mobilization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 50. Global Homecare Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Homecare Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Homecare Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 60. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 62. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 63. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Filgrastim & Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Asia-Pacific Filgrastim & Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 72. Asia-Pacific Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 73. Asia-Pacific Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 74. Asia-Pacific Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 75. Asia-Pacific Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 76. Asia-Pacific Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 77. Asia-Pacific Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 78. Asia-Pacific Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 79. North America Filgrastim & Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. North America Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 81. North America Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 82. North America Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 83. North America Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 84. North America Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 85. North America Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 86. North America Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 87. North America Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 88. Latin America Filgrastim & Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Latin America Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 90. Latin America Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 91. Latin America Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 92. Latin America Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 93. Latin America Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 94. Latin America Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 95. Latin America Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 96. Latin America Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 97. Europe Filgrastim & Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Europe Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 99. Europe Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 100. Europe Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 101. Europe Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 102. Europe Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 103. Europe Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 104. Europe Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 105. Europe Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 106. Middle East Filgrastim & Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Middle East Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 108. Middle East Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 109. Middle East Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 110. Middle East Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 111. Middle East Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 112. Middle East Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 113. Middle East Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. Middle East Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. Africa Filgrastim & Biosimilars Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 116. Africa Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 117. Africa Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 118. Africa Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 119. Africa Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 120. Africa Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 121. Africa Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 122. Africa Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 123. Africa Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 124. Global Filgrastim & Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. ASEAN Filgrastim & Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 126. ASEAN Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 127. ASEAN Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 128. ASEAN Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 129. ASEAN Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 130. ASEAN Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 131. ASEAN Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 132. ASEAN Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 133. ASEAN Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. GCC Filgrastim & Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 135. GCC Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 136. GCC Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 137. GCC Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 138. GCC Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 139. GCC Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 140. GCC Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 141. GCC Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 142. GCC Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 143. European Union Filgrastim & Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. European Union Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 145. European Union Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 146. European Union Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 147. European Union Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 148. European Union Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 149. European Union Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 150. European Union Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 151. European Union Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 152. BRICS Filgrastim & Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. BRICS Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 154. BRICS Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 155. BRICS Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 156. BRICS Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 157. BRICS Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 158. BRICS Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 159. BRICS Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 160. BRICS Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 161. G7 Filgrastim & Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 162. G7 Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 163. G7 Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 164. G7 Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 165. G7 Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 166. G7 Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 167. G7 Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 168. G7 Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 169. G7 Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. NATO Filgrastim & Biosimilars Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 171. NATO Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 172. NATO Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 173. NATO Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 174. NATO Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 175. NATO Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 176. NATO Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 177. NATO Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 178. NATO Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 179. Global Filgrastim & Biosimilars Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 180. United States Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 181. United States Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 182. United States Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 183. United States Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 184. United States Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 185. United States Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 186. United States Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 187. United States Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 188. United States Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 189. Canada Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 190. Canada Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 191. Canada Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 192. Canada Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 193. Canada Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 194. Canada Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 195. Canada Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 196. Canada Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 197. Canada Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 198. Mexico Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 199. Mexico Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 200. Mexico Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 201. Mexico Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 202. Mexico Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 203. Mexico Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 204. Mexico Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 205. Mexico Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 206. Mexico Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 207. Brazil Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 208. Brazil Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 209. Brazil Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 210. Brazil Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 211. Brazil Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 212. Brazil Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 213. Brazil Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 214. Brazil Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 215. Brazil Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 216. United Kingdom Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 217. United Kingdom Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 218. United Kingdom Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 219. United Kingdom Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 220. United Kingdom Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 221. United Kingdom Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 222. United Kingdom Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 223. United Kingdom Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 224. United Kingdom Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 225. Germany Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 226. Germany Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 227. Germany Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 228. Germany Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 229. Germany Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 230. Germany Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 231. Germany Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 232. Germany Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 233. Germany Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 234. France Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 235. France Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 236. France Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 237. France Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 238. France Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 239. France Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 240. France Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 241. France Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 242. France Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 243. Russia Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 244. Russia Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 245. Russia Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 246. Russia Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 247. Russia Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 248. Russia Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 249. Russia Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 250. Russia Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 251. Russia Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 252. Italy Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 253. Italy Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 254. Italy Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 255. Italy Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 256. Italy Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 257. Italy Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 258. Italy Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 259. Italy Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 260. Italy Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 261. Spain Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 262. Spain Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 263. Spain Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 264. Spain Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 265. Spain Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 266. Spain Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 267. Spain Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 268. Spain Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 269. Spain Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 270. China Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 271. China Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 272. China Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 273. China Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 274. China Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 275. China Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 276. China Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 277. China Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 278. China Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 279. India Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 280. India Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 281. India Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 282. India Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 283. India Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 284. India Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 285. India Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 286. India Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 287. India Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 288. Japan Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 289. Japan Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 290. Japan Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 291. Japan Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 292. Japan Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 293. Japan Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 294. Japan Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 295. Japan Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 296. Japan Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 297. Australia Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 298. Australia Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 299. Australia Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 300. Australia Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 301. Australia Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 302. Australia Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 303. Australia Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 304. Australia Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 305. Australia Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 306. South Korea Filgrastim & Biosimilars Market Size, 2017-2032 (USD Million)
  • TABLE 307. South Korea Filgrastim & Biosimilars Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 308. South Korea Filgrastim & Biosimilars Market Size, by Biosimilar Filgrastim, 2017-2032 (USD Million)
  • TABLE 309. South Korea Filgrastim & Biosimilars Market Size, by Dosage Form, 2017-2032 (USD Million)
  • TABLE 310. South Korea Filgrastim & Biosimilars Market Size, by Strength, 2017-2032 (USD Million)
  • TABLE 311. South Korea Filgrastim & Biosimilars Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 312. South Korea Filgrastim & Biosimilars Market Size, by Chemotherapy Induced Neutropenia, 2017-2032 (USD Million)
  • TABLE 313. South Korea Filgrastim & Biosimilars Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 314. South Korea Filgrastim & Biosimilars Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 315. Global Filgrastim & Biosimilars Market Share, by Key Player, 2025
  • TABLE 316. Global Filgrastim & Biosimilars Market, Key Experts